Assessing Amneal Pharmaceuticals (AMRX) Valuation Following FDA Approval for Generic Omnipaque Launch in 2026

Amneal Pharmaceuticals (AMRX) has secured FDA approval for its generic iohexol injection, becoming the first company to challenge GE Healthcare’s long-standing Omnipaque. The launch is scheduled for early 2026 and targets a sizable U.S. market opportunity.

See our latest analysis for Amneal Pharmaceuticals.

Amneal’s generic approval appears to have sparked fresh enthusiasm among investors, with the share price returning 56.6% so far this year and up 15.2% in the past month alone. The stock’s three-year total shareholder return of over 400% highlights a remarkable turnaround and suggests momentum is building as the company captures new growth opportunities.

If you’re curious about other pharmaceutical names making waves, it’s a great moment to discover See the full list for free.

With shares surging and new growth drivers on the horizon, the real question now is whether Amneal’s stock still offers value for buyers or if future gains have already been factored in by the market.

Most Popular Narrative: 10% Undervalued

With a fair value estimate of $13.50, the current close at $12.15 gives Amneal Pharmaceuticals some room to run in the eyes of consensus analysts. The latest narrative explains what is powering this gap and which strategic moves may sustain it.

Strategic partnerships (such as with Metsera for GLP-1s and ApiJect for U.S. injectables), expansion into high-growth categories (GLP-1s, complex injectables, and biosimilars), and the upcoming launches in international markets (particularly India and Europe) provide new avenues for incremental revenue and profit growth in the coming years.

Read the complete narrative.

Curious which bold assumptions are driving this premium? The narrative’s fair value hinges on rapid profit growth and margin transformation, which are uncommon in this space. Which future milestones must Amneal hit for analysts’ targets to hold up? Peek inside to uncover the surprising projections underpinning this upside call.

Result: Fair Value of $13.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, intense pricing pressure in U.S. generics and delays in pipeline launches could easily challenge this optimistic outlook for Amneal as the company moves forward.

Find out about the key risks to this Amneal Pharmaceuticals narrative.

Build Your Own Amneal Pharmaceuticals Narrative

If you prefer a different perspective or want to dig into the numbers yourself, you can craft your own story in just minutes and Do it your way.

A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Don’t settle for just one opportunity when you could be tapping into a range of promising stocks. Here are three quick ways to unlock your next smart move:

• Spot opportunities in emerging tech by evaluating market leaders among these 26 AI penny stocks. See which companies are setting the pace in artificial intelligence.
• Boost your portfolio’s income potential by reviewing companies offering exceptional yields with these 14 dividend stocks with yields > 3% on the market today.
• Get ahead with companies trading below their intrinsic worth by searching for top picks via these 924 undervalued stocks based on cash flows. Don’t let value slip by.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com